U.S. Marine and Shipping Stock News

Laughing Water Capital’s recent decision to add AnaptysBio (ANAB) has drawn attention because it hinges on two factors: royalty income from the cancer drug Jemperli and an imminent commercial trial with partner GSK. See our latest analysis for AnaptysBio. Despite the recent legal spotlight, AnaptysBio’s share price has been volatile, with a 1-day share price return down 10.46% and a 7-day share price return down 7.15%. However, a year-to-date share price return of 39.07% sits alongside a very...

Sabine Royalty Trust recently reported past production results for July 2026, with oil output of 54,139 bbls and gas production of 1,074,976 Mcf, alongside a reduced monthly cash distribution of US$0.429150 per unit declared by Argent Trust Company for payment on July 29, 2026. This combination of higher reported production volumes but a lower declared distribution highlights how the trust’s payout can diverge from short-term operational trends. Next, we will examine how the reduced July...

Wells Fargo has more than doubled investors' money over the past five years, yet its current checks suggest the stock still trades at a discount, with both the intrinsic value estimate and earnings multiples pointing to potential undervaluation rather than excess optimism. A 114.5% return over five years suggests Wells Fargo has already rewarded patient shareholders, so any perceived discount now matters more for future risk and reward. Recent earnings strength and higher capital returns can...

US growth stocks are back in focus after softer US inflation data eased pressure on interest rates, energy costs steadied and fresh signals emerged from the semiconductor and AI space. For investors trying to sort potential opportunities from risks, this mix of macro news and sector stories can matter as much as any single earnings print. This article walks through 3 US growth stocks from our screener that are exposed to these catalysts, explaining how each could be helped or hurt by the...

Agenus (AGEN) is back in focus after fresh Phase 1b data on its botensilimab plus balstilimab regimen in refractory microsatellite stable metastatic colorectal cancer, as well as an oversubscribed private placement tied to its planned ROBBIN Phase 3 trial. See our latest analysis for Agenus. Agenus has been highly volatile, with the share price return up 45.1% over the past week and 57.3% year to date, but the 1 year total shareholder return is still down 18.3% and the 5 year total...

Redwire (NYSE:RDW) secured US$21.5 million in follow-on awards to supply uncrewed aircraft systems to the U.S. Marine Corps. The contracts cover additional Advanced Stalker Block 30 systems that align with the Marine Corps' ISR modernization plans. The awards extend an existing relationship, reflecting continued use of Redwire's platform in U.S. defense programs. For investors tracking Redwire, this latest contract underscores the company’s role in supplying uncrewed aircraft systems to...

Fresh attention on Aveanna Healthcare Holdings (AVAH) has been triggered by recent coverage highlighting its value profile, as P/E, P/S, and P/CF ratios point to a potentially undervalued stock with a positive earnings outlook. See our latest analysis for Aveanna Healthcare Holdings. The recent focus on Aveanna Healthcare Holdings comes after a sharp 31.73% 1 month share price return and a 90 day share price gain of 38.99%, while the 1 year total shareholder return is 131.19% and the 3 year...

After a very strong run over the past five years, Modine Manufacturing now screens as only fairly valued on a Discounted Cash Flow (DCF) intrinsic value estimate, while traditional market multiples suggest that the stock is on the expensive side. Modine Manufacturing has delivered a very large 5 year return of about 13x, which means recent buyers are stepping into a stock that has already rewarded long term holders significantly. The planned combination of Modine's Performance Technologies...

Carnival Corporation is highlighting its Alaska business as a key long-term growth driver, with a focus on integrated cruise and land experiences. The company is investing in higher-value Alaska packages, including expansion of its Denali lodge facilities. This shift positions Alaska as a central part of Carnival's broader business strategy for future expansion. Carnival (NYSE:CCL) is putting fresh emphasis on Alaska at a time when its stock trades around $26.5, with a mixed return profile...

Trade Desk (NasdaqGM:TTD) has launched a major retail data integration with SEVEN-ELEVEN JAPAN. The partnership allows advertisers in Japan to use retail purchase data from 28 million 7-Eleven App members across digital channels. The integration focuses on scalable, always-on audience targeting that aims to respect consumer privacy requirements. Trade Desk operates a global advertising technology platform that connects advertisers to digital media across formats such as display, video, and...

ASML Holding (NasdaqGS:ASML) reports strong Q2 2026 results and raises its quarterly and full-year 2026 sales and margin guidance. Intel Foundry uses ASML's High NA EUV tools for production chips, marking the first high-volume output on this new lithography standard. Management cites robust AI-related demand and outlines plans for significant capacity expansion to support customers. ASML Holding sits at the center of advanced chip production, supplying lithography systems that are essential...

GRAIL (GRAL) is in focus after multiple law firms filed securities fraud class action lawsuits, following disclosure that its NHS Galleri cancer trial did not meet its primary endpoint and was linked to sharp investor losses. See our latest analysis for GRAIL. After the initial 50% drop following the NHS Galleri trial disclosure, GRAIL's recent momentum has picked up, with a 30 day share price return of 22.17% and a 90 day share price return of 46.86%. The 1 year total shareholder return...

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals in a US$10b all cash transaction. The deal brings atumelnant, an advanced clinical stage drug candidate for congenital adrenal hyperplasia, into Vertex's pipeline. The acquisition marks a move by Vertex into adrenal disease therapeutics, expanding beyond its traditional focus areas. For investors following Vertex Pharmaceuticals, this deal signals a push beyond the company’s established franchises and into...

We wouldn't blame SharkNinja, Inc. ( NYSE:SN ) shareholders if they were a little worried about the fact that CJ Xuning...

We wouldn't blame Arcus Biosciences, Inc. ( NYSE:RCUS ) shareholders if they were a little worried about the fact that...

The proposed US$53b bid by Stripe and Advent International for PayPal has pushed digital payments and broader fintech back into the spotlight, with a 28% offer premium hinting at how highly some buyers value this space. For investors, that kind of interest can reshape expectations across the sector, from transaction platforms to tech driven financial services. This article looks at three fintech stocks from our Fintech Sector Stocks screener that are closely tied to this news and explains how...

Arcos Dorados Holdings has delivered a 66.4% gain over the past five years, yet current valuation work suggests the stock may still trade below its intrinsic value, even after a softer recent patch for the share price. Arcos Dorados Holdings is up 66.4% over five years, which puts the current debate squarely on whether that longer term return already reflects the value in the business. The planned redemption of the 6.125% sustainability linked senior notes can support lower interest costs...

Equity Bancshares, Inc. reported second-quarter 2026 results showing net interest income of US$73.87 million, net income of US$26.44 million, basic EPS of US$1.28, and net charge-offs of US$1.7 million, while completing a buyback of 883,707 shares for US$39.09 million. Together, the earnings strength, controlled credit costs, and completion of a multi-quarter share repurchase program highlight management’s focus on profitability and capital deployment. Next, we’ll examine how this strong...

Kaspi.kz (NasdaqGS:KSPI) has introduced Kasper, a new personal AI assistant announced at a company event in Almaty, aiming to personalize how more than 25 million consumers interact with its Super App services. See our latest analysis for Kaspi.kz. Kaspi.kz’s recent Kasper launch lands after a period of solid momentum, with a 30 day share price return of 10.71% and a year to date share price return of 15.02%. The 1 year total shareholder return stands at 10.76%, pointing to interest that has...

Federal research funding is moving into the political spotlight, and that shift could matter a lot for US defense and aerospace stocks. Proposed rules that tighten control over grants, limit international collaboration, and scrutinize diversity related projects may reorder where money, talent, and research momentum flow. For investors, that creates both potential openings and new areas of risk. This article explains how the news could affect US Domestic Defense and Aerospace Stocks and...

CDW stock has fallen about 23% over the past three years, yet the current market price of US$139.38 still screens as cheap against its intrinsic value estimate from a Discounted Cash Flow (DCF) model and against earnings based multiples. The share price has declined 22.7% over three years, which means anyone looking at CDW today is assessing a stock that has already seen a meaningful reset. For long term holders, the key support for valuation is CDW's ability to convert revenue into steady...

Some Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shareholders may be a little concerned to see that the Chief Legal...

Over the last 7 days, the United States market has remained flat, yet it has experienced a robust 20% increase over the past year with earnings forecasted to grow by 18% annually. In this environment, identifying small-cap stocks that are perceived as undervalued and show insider activity can offer intriguing opportunities for investors seeking potential growth.

In the last week, the United States market has stayed flat, yet it is up 20% over the past year with earnings forecasted to grow by 18% annually. In this environment, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors seeking opportunities in potentially undervalued assets.